On Tuesday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $23.53 which represents a slight increase of $2.54 or 12.10% from the prior close of $20.99. The stock opened at ...

Citi analyst Daniel Grosslight has maintained their neutral stance on HIMS stock, giving a Hold rating on November 6. Daniel ...

Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.’s latest push into healthcare will ...

Health and wellness platform Hims & Hers Health, Inc. (NYSE:HIMS), which has gained traction for its obesity-related ...

Investors with a lot of money to spend have taken a bullish stance on Hims & Hers Health HIMS. And retail traders should know ...

Related reading: Hello Cake Review – Are Their Dissolvable ED Meds Legit? Sildenafil citrate (Generic Viagra ... minutes ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

Hims & Hers Health (NYSE: HIMS) reported another blowout quarter recently, but the stock didn't get the type of pop that ...

Hims & Hers Health, Inc. (NYSE:HIMS) investors will be delighted, with the company turning in some strong numbers with its latest results. It was overall a positive result, with revenues beating ...

Attackers create a legitimate, paid DocuSign account that allows them to change templates which they use to craft special templates mimicking requests to e-sign documents from well-known brands ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.